Although further investigations are required to thoroughly examine the possible impacts of piR-1742 suppression, the findings of the current study clearly show that piR-1742 could be a therapeutic target for the successful treatment of RCC. This evidence concerns the gene PIR and renal cell adenocarcinoma.